This story of Jason Star Was first published In Wilston Observer on March 20.
In front of the UVM, Alan Brook Lin, the second largest recipient of the National Institute of Health (NIH) in Vermont, is a business of MBF Bio -Science on Alan Brook Lin.
On this fiscal year, the company was awarded a grant of about $ 10 million and has two applications pending. Therefore, co -founder Jack Glasser (readers can recognize the Glazer with the request of the sub -division of the “Glazer Parcel” on Mountain View Road) by meeting the Trump administration to reduce the grant allowance by meeting the administrative costs.
MBF bio -science produces products used in biomedical research products. Not only does it receive NIH grants for research and development, but it also sells products to researchers whose work is financed by NIH.
“This is a huge part of our business,” Glazer said about the NIH grant funding. “
About three weeks after Donald Trump’s president, NIH justified the change, justifying the change, in the debate that many of the organization’s grant awards are used on accounting such as “indirect costs” such as construction work, equipment and administrative works. According to the memo date on February 7, it announced a cap on these expenditures at 15 % of any new or current grant award.
“NIH spent more than 35,000 researchers more than 35,000 universities, medical schools and other research institutes on more than 35,000 universities, medical schools and other research institutes on more than 35,000 $ 35,000 on a competitive grant in the financial year 2023.
The agency reports an average cost rate on its grant of about 27 27 %, while noting that some private non-profit foundation does not fund indirect expenditures for scientific research, and other indirect costs keep between 10-15 %.
Due to a court order, which stopped the change in policy, the Glazer expects the recently approved complete million to receive 1 million, but two pending applications were stopped. The Glazer said that the reason was that the NIH had managed to freeze de facto funding by postponing public meetings to review the Grant Awards.
“The answer was (on the judge’s order),” Oh, we will not only allow the NIH to decide who will get the fund, “the Glazer said. “So there is basically a block right now. This is a backdoor block that the Trump administration forbade NIH from using the system to declare public meetings.”
MBF Bio -Science has employed close to 35 people outside its Wilston Office, and also has offices in Virginia, San Diego, the Netherlands and Japan. The Glazer hopes that its international business and the sale of NIH in private pharmaceuticals and biotech companies will not be affected. But if the courts eventually allow a reduction in grant, which is looking for the Trump administration, the company has done a significant loss to the method of doing business during its nearly 40 -year history.
“Not everything is permanent on NIH’s financing, but the way we have been working for years, it is definitely dependent on receiving funds for the development of NIH’s new products,” Glazer said.
While he described this business career’s most difficult time, he said he was more concerned about the ecosystem of American scientific research. A blog post on the company’s website (MBFBI Science.com) explains: “Scientific progress is not overnight. It is the result of permanent funds, cooperation and commitment. The severe reduction in the budget will prevent plans, disrupt the labs, and the talented researchers-especially the preliminary career-effects.
Vermont Attorney General Charity Clark echoed the sentiment when he announced a case filed with fellow Democratic Attorney General in 21 other states.
“Medical research funding through NIH grant has led to numerous scientific achievements, including the discovery of all types of cancer treatment, the first setting of DNA and the development of MRI. In addition, dozens of NIH -run -based scientists have received awards belonging to their office.”
His office estimates that the NIH financing reduction is about $ 120 million in Vermont.
NIH argues that the new policy aims to smooth the country’s biochemical research.
“The United States should have the best medical research in the world,” said the February 7 memo. “Accordingly, it is important to ensure that more funds go directly to scientific research costs rather than administrative overhead.”
